Literature DB >> 18634736

Perception of abnormal serum prostate-specific antigen (PSA) test results amongst family practitioners.

M A Rochester1, P J Donaldson, J McLoughlin.   

Abstract

INTRODUCTION: With increased use of serum prostate-specific antigen (PSA) testing, prostate cancers are diagnosed at an earlier stage in younger men, when radical curative treatments are appropriate. Modifications of the PSA test such as PSA velocity and age-adjusted values are available to aid in the selection of patients for biopsy. However, it is not clear whether these data are used in general practice. PATIENTS AND METHODS: A self-administered questionnaire was mailed to all primary care practices within one region in the UK. A series of visual analogue questions designed to identify referral thresholds for age-adjusted PSA levels and PSA velocity were used to identify patterns in referral behaviour.
RESULTS: Individual family practitioners see only small numbers of patients requesting PSA tests or with newly diagnosed prostate cancer each year. The median (range) thresholds considered for referral at ages 45, 55, 65, 75 and 85 years were 4.5 ng/ml (2.5-15.5 ng/ml), 5.5 ng/ml (3.0-15.5 ng/ml), 6.5 ng/ml (3.5-15.5 ng/ml), 6.5 ng/ml (3.5-25.5 ng/ml), and 7.5 ng/ml (3.5-25.5 ng/ml), respectively. Only 5% of practitioners correctly identified the age-specific PSA threshold for referral of a 45-year-old man.
CONCLUSIONS: It is important to remember that younger men (even those in their forties and fifties) may be at risk of prostate cancer even if asymptomatic. It is important in a climate of increasing demand for PSA testing that those who initiate the process understand the implications and limitations of testing, including appropriate triggers for referral to secondary care. The exact approach required for the successful dissemination of this information to primary care is not clear, but our data suggest that a better understanding is required.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18634736      PMCID: PMC2645742          DOI: 10.1308/003588408X301019

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  13 in total

1.  Promoting better use of the PSA test in general practice: randomized controlled trial of educational strategies based on outreach visits and mailout.

Authors:  D Weller; F May; D Rowett; A Esterman; C Pinnock; S Nicholson; J Doust; C Silagy
Journal:  Fam Pract       Date:  2003-12       Impact factor: 2.267

2.  Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994.

Authors:  L M Newcomer; J L Stanford; B A Blumenstein; M K Brawer
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

3.  Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

Authors:  Ingrid W van der Cruijsen-Koeter; André N Vis; Monique J Roobol; Mark F Wildhagen; Harry J de Koning; Theo H van der Kwast; Fritz H Schröder
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

4.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

5.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

6.  Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study.

Authors:  Jane Melia; Sue Moss; Louise Johns
Journal:  BJU Int       Date:  2004-07       Impact factor: 5.588

7.  Evidence of prostate cancer screening in a UK region.

Authors:  A Gavin; P McCarron; R J Middleton; G Savage; D Catney; D O'Reilly; P F Keane; L J Murray
Journal:  BJU Int       Date:  2004-04       Impact factor: 5.588

8.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

9.  PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.

Authors:  Jo Brett; Eila Watson; Paul Hewitson; Colleen Bukach; Adrian Edwards; Glyn Elwyn; Joan Austoker
Journal:  BMC Fam Pract       Date:  2005-06-09       Impact factor: 2.497

10.  Survey of the rate of PSA testing in general practice.

Authors:  J Melia; S Moss
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

View more
  3 in total

1.  [Rates of prostate-specific antigen testing for early detection of prostate cancer: a first comparison of German results with current international data].

Authors:  S Lebentrau; M May; O Maurer; M Schostak; M Lehsnau; T Ecke; S Al-Dumaini; S Hallmann; A M Ahmed; V Braun; A Haferkamp; R M Bauer; C G Stief; D Baumunk; B Hoschke; H-P Braun; C Schäfer; M Hipp; J Maurer; K-P Braun; I Wolff; S Brookman-May; C Gilfrich
Journal:  Urologe A       Date:  2014-05       Impact factor: 0.639

Review 2.  Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review.

Authors:  Saskia Van der Meer; Sabine A M Löwik; Willem H Hirdes; Rien M Nijman; Klaas Van der Meer; Josette E H M Hoekstra-Weebers; Marco H Blanker
Journal:  BMC Fam Pract       Date:  2012-10-11       Impact factor: 2.497

3.  General practitioner perception of prostate-specific antigen testing has improved, but more awareness of prostate cancer risk in younger patients is still awaited.

Authors:  David R Thurtle; Emma M Gordon; Robert D Brierly; Ciaran J Conway; John McLoughlin
Journal:  Prostate Int       Date:  2017-10-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.